Clinical Trial Update: Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD [Phase 1]

View source ↗

Summary

Phase 1 trial of deutetrabenazine for dysphagia in Huntington disease was terminated; no conclusive efficacy results are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• AUSTEDO (deutetrabenazine)

Snippet

Sponsor: Fundacion Huntington Puerto Rico | Conditions: Huntington Disease | Phase 1 | Status: TERMINATED